POLI

DNA polymerase iota · Q9UNA4 · POLI on Sugi Atlas →

66 patent compounds predicted against POLI, 58 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Aurintricarboxylic Acid (SCHEMBL98495)	1.00	1/20
Aurintricarboxylic Acid (SCHEMBL29353681)	1.00	1/20
Aurintricarboxylic Acid (SCHEMBL29450069)	1.00	1/20
Aurintricarboxylic Acid (SCHEMBL515038)	0.97	1/20
Aurintricarboxylic Acid (SCHEMBL4644958)	0.97	1/20
Aurintricarboxylic Acid (SCHEMBL6158321)	0.97	1/20
Aurintricarboxylic Acid (SCHEMBL10791075)	0.97	1/20
Aurintricarboxylic Acid (SCHEMBL15874321)	0.97	1/20
Aurintricarboxylic Acid (SCHEMBL29395768)	0.97	1/20
Aurintricarboxylic Acid (SCHEMBL30831678)	0.97	1/20
Aurintricarboxylic Acid (SCHEMBL6847597)	0.95	1/20
SCHEMBL13161169	0.88	1/20
Aurintricarboxylic Acid (SCHEMBL7931573)	0.81	1/20
SCHEMBL9755148	0.80	1/20
SCHEMBL14269440	0.80	1/20
SCHEMBL25438838	0.79	1/20
SCHEMBL10028458	0.77	1/20
SCHEMBL12634308	0.76	1/20
SCHEMBL4918769	0.74	1/20
SCHEMBL14259733	0.73	1/20

Clinical trials — most relevant to POLI by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Locally Delivered Doxycycline Adjunct to Nonsurgical Periodontal Therapy.	PHASE4	COMPLETED
Intracameral Antibiotic Safety Study	PHASE3	SUSPENDED
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection	PHASE3	UNKNOWN
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer	PHASE2	COMPLETED
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer	PHASE2	UNKNOWN
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide	PHASE2	ACTIVE_NOT_RECRUITING
Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)	PHASE2	RECRUITING
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
Topotecan for Irinotecan-Refractory SCLC	PHASE2	UNKNOWN
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib	PHASE2	COMPLETED
Precision Cancer Therapy in Rare Cancers	PHASE2	RECRUITING
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer	PHASE2	RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts	PHASE1	ACTIVE_NOT_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems	PHASE1	WITHDRAWN
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors	PHASE1	COMPLETED
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer	nan	NOT_YET_RECRUITING
REal Word aPpLicAtion of Molecular Based Endometrial Cancer Classification	nan	RECRUITING
Cohort of Tumors With POLE/D1 Mutation	nan	RECRUITING
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a POLI binder may also engage these)

Protein	Name	Similarity
Q6R3M4	—	0.994	Q6R3M4 →
Q5R4N7	—	0.984	Q5R4N7 →
Q8H2D5	—	0.980	Q8H2D5 →
REV1	DNA repair protein REV1	0.980	landscape →
Q920Q2	—	0.979	Q920Q2 →
ERCC5	DNA excision repair protein ERCC-5	0.977	landscape →
Q4KWZ7	—	0.976	Q4KWZ7 →
P14629	—	0.976	P14629 →
Q5RCV3	—	0.975	Q5RCV3 →
Q8NAT2	—	0.975	Q8NAT2 →
Q9QUG2	—	0.974	Q9QUG2 →
O60934	—	0.974	O60934 →
DDX20	Probable ATP-dependent RNA helicase DDX20	0.973	landscape →
Q8BMI4	—	0.973	Q8BMI4 →
Q5XIX3	—	0.972	Q5XIX3 →
Q9QXK2	—	0.972	Q9QXK2 →
Q9R207	—	0.972	Q9R207 →
Q17RS7	—	0.972	Q17RS7 →
Q9JJY4	—	0.972	Q9JJY4 →
Q7TPQ3	—	0.971	Q7TPQ3 →
P0C218	—	0.971	P0C218 →
Q8GT06	—	0.971	Q8GT06 →
Q60GC1	—	0.971	Q60GC1 →
RAD18	E3 ubiquitin-protein ligase RAD18	0.971	landscape →
B2GUN4	—	0.970	B2GUN4 →
E2QTD3	—	0.970	E2QTD3 →
Q69Z66	—	0.969	Q69Z66 →
Q5R652	—	0.969	Q5R652 →
F1SRY5	—	0.969	F1SRY5 →
Q9Y620	—	0.969	Q9Y620 →